OncoMatch/Clinical Trials/NCT02526368
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
Is NCT02526368 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Hyperpolarized 13C-Pyruvate and Hyperpolarized 13C,15N2-urea for prostate cancer.
Treatment: Hyperpolarized 13C-Pyruvate · Hyperpolarized 13C,15N2-urea — This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon (13C) pyruvate, may aid in the diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer and benign adjacent prostate tissue
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cryosurgery
Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment. For Cohort B, HIFU focal therapy is allowed.
Cannot have received: surgery for prostate cancer
Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment. For Cohort B, HIFU focal therapy is allowed.
Cannot have received: prostatic or pelvic radiotherapy
Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment. For Cohort B, HIFU focal therapy is allowed.
Cannot have received: androgen deprivation therapy
Current or prior androgen deprivation therapy. For Cohort A, a history of use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry. For cohort B, a history of use of 5-α reductase inhibitor is allowed, provided it is discontinued at least 14 days to protocol MRI/MRSI.
Cannot have received: transurethral prostatic resection (TURP)
prior transurethral prostatic resection (TURP) is not allowed
Lab requirements
Blood counts
Absolute neutrophil count (ANC) >= 1500 cells/microliter (uL); Hemoglobin >= 9.0 mg/dL; Platelets >= 75,000 cells/uL
Kidney function
Estimated creatinine clearance >= 50 mL/min (by the Cockcroft Gault equation)
Liver function
Bilirubin < 1.5 x upper limit of normal (ULN) (unless Gilbert's is suspected); AST and ALT < 1.5 x ULN
Absolute neutrophil count (ANC) >= 1500 cells/microliter (uL); Hemoglobin >= 9.0 mg/dL; Platelets >= 75,000 cells/uL; Estimated creatinine clearance >= 50 mL/min (by the Cockcroft Gault equation); Bilirubin < 1.5 x upper limit of normal (ULN) (unless Gilbert's is suspected); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify